Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Radiopharmaceuticals

Radiopharma Powerhouses Push Frontiers With New Indications, Innovation

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a radiopharmaceuticals market that could top $16 billion by 2033.

May 12, 2025

9 min read

Tristan Manalac

Rack with tubes blood samples from patients for analysis in the hematology lab .

Opinion

Bringing Neurological Disease Into the Age of Precision Medicine

To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of protein aggregates in the brain.

May 12, 2025

5 min read

John McDonough

Corona virus, Covid-19 and social distancing concept surreal artwork, painting illustration, lonely with floating virus, illustration

Infectious disease

Biopharma Targets an HIV Cure as NIH Funding Cuts Threaten To Derail Progress

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are targeting the next goalpost: a cure.

May 12, 2025

7 min read

Heather McKenzie

Illustration of people amidst global map images holding back walls falling down

Editorial

Doubts About Job Market Turning Around Soon Easy To Understand

In a recent BioSpace LinkedIn poll, nearly half of respondents predicted the job market won’t turn around until 2027 or later. It’s easy to see why people are skeptical, especially when you consider recent hiring activity and layoffs.

May 9, 2025

3 min read

Angela Gabriel

Storm moody sky over White House, residence and workplace of the president of the United States, concept shot

Editorial

Rest Up, Biopharma. Trump’s Drug Pricing Policy Is Coming on Monday

With President Donald Trump expected to deliver a drug pricing order on Monday that Big Pharma and patient groups alike have railed against, the industry’s tumultuous ride is far from over.

May 9, 2025

4 min read

Annalee Armstrong

Employees Walking In And Out Of The Door, Some Were Leaving Their Job And Some Were Being Hired At The Same Time. Full Length, Isolated On Solid Color Background. Vector, Illustration, Flat Design, Character.

Layoffs

Insitro Cuts 22% of Workforce, Extending Runway Into 2027

Insitro’s layoffs affect about 65 employees as the AI-focused biotech looks to advance its pipeline in metabolic disease and neuroscience.

May 9, 2025

2 min read

Angela Gabriel

Hands tearing money over red background. Professional challenges, disagreement, greed. Contemporary art collage. Concept of financial literacy, economic, business, money

Layoffs

Sanofi Cuts Off Antibody Partner, Forcing 80% Headcount Reduction at IGM

After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review of potential strategic alternatives and options for the business.

May 9, 2025

2 min read

Tristan Manalac